To evaluate the clinical mechanism of Lianhua Qingwen Capsule on the systemic immune regulation of patients with new coronavirus pneumonia

INTERVENTION: Lianhua Qingwen Group:Capsules 4 capsules / time, 3 times a day;Basic treatment group:In principle, no drugs and other treatments are used; CONDITION: Coronavirus diseaseNovel Coronavirus Pneumonia (COVID-19) PRIMARY OUTCOME: Inflammatory factors;Immune cell genus; INCLUSION CRITERIA: 1. Aged 18 to 59 years; 2. Refer to the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Eighth Edition)" formulated by the National Health Commission, with evidence of etiology or serology, and confirmed mild patients with new coronavirus pneumonia (mild clinical symptoms, no imaging Pneumonia manifestations). 3. The weight of male subjects must be >=50 kg, and the weight of female subjects >=45kg; body mass index (BMI=weight (kg) / height (m) square calculation) between 19 and 26 (including cutoff values)); 4. The subject understands and accepts the process and restriction requirements of this study, voluntarily participates in this clinical study, and signs a written informed consent form